Literature DB >> 27152162

New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism.

L Cristino1, L Palomba2, V Di Marzo1.   

Abstract

Excessive consumption of high-energy, palatable food contributes to obesity, which results in the metabolic syndrome, heart disease, type-2 diabetes and death. Current knowledge on the function of the hypothalamus as the brain 'feeding centre' recognizes this region as the main regulator of body weight in the central nervous system. Because of their intrinsically fast and adaptive activities, feeding-controlling neural circuitries are endowed with synaptic plasticity modulated by neurotransmitters and hormones that act at different hierarchical levels of integration. In the hypothalamus, among the chemical mediators involved in this integration, endocannabinoids (eCBs) are ideal candidates for the fast (that is, non-genomic), stress-related fine-tuning of neuronal functions. In this article, we overview the role of the eCB system (ECS) in the control of energy intake, and particularly in the consumption of high-energy, palatable food, and discuss how such a role is affected in the brain by changes in the levels of feeding-regulated hormones, such as the adipose tissue-derived anorexigenic mediator leptin, as well as by high-fat diets. The understanding of the molecular mechanisms underlying the neuronal control of feeding behaviours by eCBs offers many potential opportunities for novel therapeutic approaches against obesity. Highlights of the latest advances in the development of strategies that minimize central ECS overactivity in 'western diet'-driven obesity are discussed.

Entities:  

Keywords:  CB1; endocannabinoids; high-fat diet; hypothalamus; leptin; synaptic rewiring

Year:  2014        PMID: 27152162      PMCID: PMC4850587          DOI: 10.1038/ijosup.2014.8

Source DB:  PubMed          Journal:  Int J Obes Suppl        ISSN: 2046-2166


  48 in total

Review 1.  Endocannabinoid modulation in the olfactory epithelium.

Authors:  Esther Breunig; Dirk Czesnik; Fabiana Piscitelli; Vincenzo Di Marzo; Ivan Manzini; Detlev Schild
Journal:  Results Probl Cell Differ       Date:  2010

2.  The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling.

Authors:  Samir Haj-Dahmane; Roh-Yu Shen
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

Review 3.  Endocannabinoid-mediated control of synaptic transmission.

Authors:  Masanobu Kano; Takako Ohno-Shosaku; Yuki Hashimotodani; Motokazu Uchigashima; Masahiko Watanabe
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

Review 4.  Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Authors:  Sara Jane Ward; Robert B Raffa
Journal:  Obesity (Silver Spring)       Date:  2011-04-07       Impact factor: 5.002

Review 5.  An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Authors:  F D Christopoulou; D N Kiortsis
Journal:  J Clin Pharm Ther       Date:  2011-02       Impact factor: 2.512

6.  Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain.

Authors:  Lumír Hanus; Yosefa Avraham; Dikla Ben-Shushan; Olga Zolotarev; Elliot M Berry; Raphael Mechoulam
Journal:  Brain Res       Date:  2003-09-05       Impact factor: 3.252

7.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors:  Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.

Authors:  Tim C Kirkham; Claire M Williams; Filomena Fezza; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

9.  Development of the first potent and specific inhibitors of endocannabinoid biosynthesis.

Authors:  Tiziana Bisogno; Maria Grazia Cascio; Bijali Saha; Anu Mahadevan; Paolo Urbani; Alberto Minassi; Giovanni Appendino; Carmela Saturnino; Billy Martin; Raj Razdan; Vincenzo Di Marzo
Journal:  Biochim Biophys Acta       Date:  2006-01-23

10.  Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons.

Authors:  Luigia Cristino; Giuseppe Busetto; Roberta Imperatore; Ida Ferrandino; Letizia Palomba; Cristoforo Silvestri; Stefania Petrosino; Pierangelo Orlando; Marina Bentivoglio; Kenneth Mackie; Vincenzo Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

View more
  7 in total

1.  Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Authors:  Nicholas Z Greene; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Psychopharmacology (Berl)       Date:  2018-09-20       Impact factor: 4.530

Review 2.  Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?

Authors:  Jürg Gertsch
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

3.  Suppressing effect of COR659 on alcohol, sucrose, and chocolate self-administration in rats: involvement of the GABAB and cannabinoid CB1 receptors.

Authors:  Paola Maccioni; Giancarlo Colombo; Irene Lorrai; Alessandro Zaru; Mauro A M Carai; Gian Luigi Gessa; Antonella Brizzi; Claudia Mugnaini; Federico Corelli
Journal:  Psychopharmacology (Berl)       Date:  2017-05-24       Impact factor: 4.530

4.  Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis.

Authors:  Yu Yong; Isin Cakir; Pauline Lining Pan; Jessica E Biddinger; Rebecca J Bluett; Ken Mackie; Nathan Bingham; Sachin Patel; Masoud Ghamari-Langroudi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-19       Impact factor: 11.205

Review 5.  Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.

Authors:  Andrew Scheyer; Farhana Yasmin; Saptarnab Naskar; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2022-09-13       Impact factor: 8.294

Review 6.  (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders.

Authors:  Jyoti Sihag; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2022-01-14       Impact factor: 3.876

7.  New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents.

Authors:  Mayank Kumar Sharma; Jatin Machhi; Prashant Murumkar; Mange Ram Yadav
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.